SCHEMBL7572608

SCHEMBL7572608

O=S(=O)(Nc1ccccc1)c1ccc(OC(F)(F)F)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.61
MEN1 O00255 2/20 0.61
ALDH1A1 P00352 1/20 0.61
PKM P14618 1/20 0.61
IL1RN P18510 1/20 0.59
KEAP1 Q14145 1/20 0.59
ERAP1 Q9NZ08 1/20 0.59
FFAR4 Q5NUL3 3/20 0.59
HDAC1 Q13547 3/20 0.59
HDAC8 Q9BY41 3/20 0.59
FFAR1 O14842 1/20 0.57
PGR P06401 1/20 0.57
HDAC3 O15379 2/20 0.56
HDAC4 P56524 2/20 0.56
HDAC7 Q8WUI4 2/20 0.56
HDAC2 Q92769 2/20 0.56
HDAC10 Q969S8 2/20 0.56
HDAC11 Q96DB2 2/20 0.56
HDAC6 Q9UBN7 2/20 0.56
HDAC9 Q9UKV0 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5598012 0.91 PGR (0.72) KMT2AMEN1FFAR4HDAC1HDAC8
SCHEMBL12010878 0.89 IDH1 (0.70) KMT2AMEN1FFAR4HDAC1HDAC8
SCHEMBL28572870 0.87 PGR (0.67) KMT2AMEN1FFAR4HDAC1HDAC8
SCHEMBL28913958 0.87 KIF11 (0.69) ALDH1A1FFAR4HDAC1HDAC8HDAC3
SCHEMBL7570513 0.86 FFAR4 (0.64) ALDH1A1FFAR4HDAC1HDAC8FFAR1
SCHEMBL18031172 0.84 HDAC1 (0.63) FFAR4HDAC1HDAC8HDAC3HDAC4
SCHEMBL6756075 0.84 FFAR4 (0.68) ALDH1A1FFAR4HDAC1HDAC8FFAR1
SCHEMBL28570269 0.84 FFAR4 (0.60) ALDH1A1FFAR4HDAC1HDAC8HDAC3
SCHEMBL5041094 0.84 FFAR4 (0.56) ALDH1A1FFAR4HDAC1HDAC8HDAC3
SCHEMBL7570765 0.84 CES1 (0.67) ALDH1A1FFAR4HDAC1HDAC8PGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230322715-A1 BROAD SPECTRUM ANTI-CANCER COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2023-10-12 US disclosed
CN-116806217-A Substituted cyclic modulators of protein phosphatase 2A (PP 2A) and methods of use thereof 拉帕塔疗法公司 2023-09-26 CN disclosed
EP-1239852-A2 BISSULFONAMIDE DERIVATIVES AS ENZYME INHIBITORS Arrow Therapeutics Limited (GB) 2002-09-18 EP disclosed
WO-2001028537-A2 BISSULFONAMIDE DERIVATIVES AS ENZYME INHIBITORS ARROW THERAPEUTICS LIMITED (GB) 2001-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230322715-A1 BROAD SPECTRUM ANTI-CANCER COMPOUNDS YTHDF1, YTHDF3, YTHDF2 KMT2A 134/4885MEN1 3143/4885ALDH1A1 4553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.